Basilea's Pivot to a Portfolio: Non-Dilutive Funding, Two Phase III Assets, and a Raised Outlook

Strong H1 2026 with 14% revenue growth, raised operating profit guidance, and a pipeline that could nearly double peak sales.

BSLN.SW · Earnings Call · 2026-08-18

A stronger financial base

Basilea Pharmaceutica entered 2026 on a wave of momentum, and the first half delivered. Total revenue rose 14% year-on-year to CHF 119 million, operating profit jumped 32% to CHF 32 million, and net cash doubled to CHF 105 million. The company also secured $61 million in non-dilutive funding, offsetting a significant portion of R&D spend. “We have had a great start to the year, delivering strong financial results and continued execution across the business.” — David Veitch, CEO · 2026-08-18 The strength is reflected in a raised full-year outlook. Management now guides for total revenue growth of approximately 15%, with Cresemba/Zevtera revenue of around CHF 210 million (up from CHF 200 million) and a ~40% increase in operating profit—versus the prior ~20% expectation. “This demonstrates the strength of our business model and our ability to maintain solid profitability while increasing investments in our growth pipeline.” — Adesh Kaul, Unknown (likely senior management, possibly CFO or commercial lead) · 2026-08-18 The balance sheet also improved with the repurchase of CHF 5 million in convertible bonds, trimming outstanding debt to CHF 71 million, due July 2027. The company ended H1 with CHF 176 million in cash and equivalents. This is a far cry from the pre-2022 era when the company was still juggling an oncology portfolio and a heavier debt load.

Pipeline maturation

The strategic shift away from oncology toward anti-infectives is now unmistakable. Basilea is building a franchise around two commercial products (Cresemba and Zevtera) and two Phase III assets—fosmanogepix and ceftibuten-ledaborbactam—with combined peak sales potential of about $1.5 billion. Ceftibuten ledaborbactam is preparing for a global Phase III program, with study initiation expected in mid-2027. “We've entered into an active discussion and the formal process with FDA and EMA for the program.” — Marc Engelhardt, Unknown (likely senior management or head of clinical development) · 2026-08-18 Fosmanogepix continues to generate real-world evidence through an expanded access program with nearly 600 patients across 22 countries. body of real world experience is growing and could complement the regulatory package. The company is also pushing antifungal candidate BAL2420—a first-in-class LptA inhibitor—into Phase I, and recently in-licenced a novel antibiotic candidate from Prokaryotics. This pipeline breadth is a clear departure from the earlier single-product dependence on Cresemba. As David Veitch put it:

Assuming successful clinical and regulatory outcomes, Fosmanogepix could become our third commercial product in 2029, followed by ceftibuten-ledaborbactam as our fourth commercial product approximately a year later.
David Veitch, CEO · 2026-08-18

What changed and why it matters

The most notable shift is financial—both in scale and in the quality of earnings. profit guidance was raised by 20 percentage points, and the company now expects operating profit to grow roughly 40% this year. This is driven by higher-margin royalties and milestones, with increase in royalties expected to accelerate in H2 as the full-year guidance implies CHF 125 million in royalty income. The second shift is external: Basilea is increasingly de-risking its R&D through non-dilutive funding. non dilutive funding now covers a meaningful portion of development costs—over $440 million committed across BARDA and CARB-X, with $165 million awarded, including $61 million this year. This allows the company to advance late-stage programs while preserving cash for potential partnerships and buybacks. Management also hinted at capital allocation priorities beyond R&D. In prior quarters, the focus was on debt reduction. Now, with net cash at CHF 105 million and a clear roadmap, the conversation is shifting towards dividends or buybacks. As Adesh Kaul said in February: “we are looking at product and contract revenue, which is basically CHF 200 million to take this year's number.” — Adesh Kaul · 2026-02-17 That number has now been revised upward, reflecting the underlying momentum. Basilea's story is becoming one of a self-sustaining specialty pharma, not just a biotech with a single blockbuster. The company is leveraging its commercial strengths (Cresemba's global growth, Zevtera's U.S. launch) to fund a deep pipeline. The market has started to notice—though the stock's reaction to this report is yet to be seen. The biggest risk remains execution: both Phase III programs must read out successfully, and Zevtera's U.S. launch is still nascent. But the bar for what constitutes success has clearly risen. Basilea is no longer a one-trick pony; it's building a franchise.